Repository logo
 

Cytokine-induced megakaryocytic differentiation is regulated by genome-wide loss of a uSTAT transcriptional program.

Published version
Peer-reviewed

Repository DOI


Type

Article

Change log

Authors

Park, HJ 
Li, J 
Biddie, S 
Leal-Cervantes, AI 

Abstract

Metazoan development is regulated by transcriptional networks, which must respond to extracellular cues including cytokines. The JAK/STAT pathway is a highly conserved regulatory module, activated by many cytokines, in which tyrosine-phosphorylated STATs (pSTATs) function as transcription factors. However, the mechanisms by which STAT activation modulates lineage-affiliated transcriptional programs are unclear. We demonstrate that in the absence of thrombopoietin (TPO), tyrosine-unphosphorylated STAT5 (uSTAT5) is present in the nucleus where it colocalizes with CTCF and represses a megakaryocytic transcriptional program. TPO-mediated phosphorylation of STAT5 triggers its genome-wide relocation to STAT consensus sites with two distinct transcriptional consequences, loss of a uSTAT5 program that restrains megakaryocytic differentiation and activation of a canonical pSTAT5-driven program which includes regulators of apoptosis and proliferation. Transcriptional repression by uSTAT5 reflects restricted access of the megakaryocytic transcription factor ERG to target genes. These results identify a previously unrecognized mechanism of cytokine-mediated differentiation.

Description

Keywords

StemCellInstitute, JAK/STAT, cytokine, differentiation, haematopoiesis, megakaryocyte

Journal Title

EMBO J

Conference Name

Journal ISSN

0261-4189
1460-2075

Volume Title

35

Publisher

EMBO press

Rights

Attribution 4.0 International
Sponsorship
Wellcome Trust (104710/Z/14/Z)
Cancer Research Uk (None)
Leukaemia & Lymphoma Research (12029)
Wellcome Trust (097922/Z/11/Z)
Medical Research Council (MC_PC_12009)
Leukemia & Lymphoma Society (7001-12)
Biotechnology and Biological Sciences Research Council (BB/I00050X/1)
Medical Research Council (MR/M008975/1)
Leukaemia & Lymphoma Research (13003)
Blood Cancer UK (07037)
Wellcome Trust (097922/Z/11/B)
Work in the Green lab is supported by Bloodwise (grant ref. 13003), the Wellcome Trust (grant ref. 104710/Z/14/Z), the Medical Research Council, the Kay Kendall Leukaemia Fund, the Cambridge NIHR Biomedical Research Center, the Cambridge Experimental Cancer Medicine Centre, the Leukemia and Lymphoma Society of America (grant ref. 07037), and a core support grant from the Wellcome Trust and MRC to the Wellcome Trust‐Medical Research Council Cambridge Stem Cell Institute. Hyun Jung Park was supported by postdoctoral fellowships from the EMBO and the Human Frontier Science Program.